Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1936 1
1958 1
1959 1
1963 1
1964 2
1965 1
1966 2
1967 4
1971 3
1972 6
1973 2
1974 7
1975 5
1976 8
1977 3
1978 6
1979 3
1980 11
1981 6
1982 5
1983 9
1984 5
1985 9
1986 15
1987 18
1988 25
1989 20
1990 24
1991 20
1992 39
1993 24
1994 42
1995 34
1996 24
1997 32
1998 18
1999 28
2000 28
2001 51
2002 71
2003 75
2004 97
2005 110
2006 149
2007 147
2008 141
2009 174
2010 235
2011 252
2012 277
2013 276
2014 308
2015 278
2016 321
2017 397
2018 410
2019 485
2020 560
2021 575
2022 646
2023 526
2024 514
2025 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6,705 results

Results by year

Filters applied: . Clear all
Page 1
Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer.
Hadoux J, Elisei R, Brose MS, Hoff AO, Robinson BG, Gao M, Jarzab B, Isaev P, Kopeckova K, Wadsley J, Führer D, Keam B, Bardet S, Sherman EJ, Tahara M, Hu MI, Singh R, Lin Y, Soldatenkova V, Wright J, Lin B, Maeda P, Capdevila J, Wirth LJ; LIBRETTO-531 Trial Investigators. Hadoux J, et al. N Engl J Med. 2023 Nov 16;389(20):1851-1861. doi: 10.1056/NEJMoa2309719. Epub 2023 Oct 21. N Engl J Med. 2023. PMID: 37870969 Clinical Trial.
Mutant NPM1 Maintains the Leukemic State through HOX Expression.
Brunetti L, Gundry MC, Sorcini D, Guzman AG, Huang YH, Ramabadran R, Gionfriddo I, Mezzasoma F, Milano F, Nabet B, Buckley DL, Kornblau SM, Lin CY, Sportoletti P, Martelli MP, Falini B, Goodell MA. Brunetti L, et al. Among authors: lin cy. Cancer Cell. 2018 Sep 10;34(3):499-512.e9. doi: 10.1016/j.ccell.2018.08.005. Cancer Cell. 2018. PMID: 30205049 Free PMC article.
Acute lymphangitis.
Tai YL, Lin CY. Tai YL, et al. Among authors: lin cy. Med J Aust. 2022 Apr 4;216(6):287. doi: 10.5694/mja2.51448. Epub 2022 Mar 10. Med J Aust. 2022. PMID: 35267196 No abstract available.
COVID-19 Vaccine Hesitancy in the United States: A Systematic Review.
Yasmin F, Najeeb H, Moeed A, Naeem U, Asghar MS, Chughtai NU, Yousaf Z, Seboka BT, Ullah I, Lin CY, Pakpour AH. Yasmin F, et al. Among authors: lin cy. Front Public Health. 2021 Nov 23;9:770985. doi: 10.3389/fpubh.2021.770985. eCollection 2021. Front Public Health. 2021. PMID: 34888288 Free PMC article.
Efficacy, safety, and immunogenicity of an inactivated, adjuvanted enterovirus 71 vaccine in infants and children: a multiregion, double-blind, randomised, placebo-controlled, phase 3 trial.
Nguyen TT, Chiu CH, Lin CY, Chiu NC, Chen PY, Le TTV, Le DN, Duong AH, Nguyen VL, Huynh TN, Truong HK, Phan TL, Nguyen TTT, Shih SR, Huang CG, Weng YJ, Hsieh EF, Chang S, Chen C, Tai IC, Huang LM. Nguyen TT, et al. Among authors: lin cy. Lancet. 2022 Apr 30;399(10336):1708-1717. doi: 10.1016/S0140-6736(22)00313-0. Epub 2022 Apr 12. Lancet. 2022. PMID: 35427481 Clinical Trial.
Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE).
Simpson EL, Flohr C, Eichenfield LF, Bieber T, Sofen H, Taïeb A, Owen R, Putnam W, Castro M, DeBusk K, Lin CY, Voulgari A, Yen K, Omachi TA. Simpson EL, et al. Among authors: lin cy. J Am Acad Dermatol. 2018 May;78(5):863-871.e11. doi: 10.1016/j.jaad.2018.01.017. Epub 2018 Jan 17. J Am Acad Dermatol. 2018. PMID: 29353026 Free article. Clinical Trial.
Treatment Responses to Integrase Strand-transfer Inhibitor-containing Antiretroviral Regimens in Combination With Short-course Rifapentine-based Regimens for Latent Tuberculosis Infection Among People With HIV.
Lin KY, Sun HY, Yang CJ, Lu PL, Lee YT, Lee NY, Liou BH, Tang HJ, Lee MH, Wang NC, Chen TC, Hii IM, Huang SH, Lin CY, Tsai CS, Cheng CY, Hung CC; Taiwan HIV Study Group. Lin KY, et al. Among authors: lin cy. Clin Infect Dis. 2024 May 15;78(5):1295-1303. doi: 10.1093/cid/ciad730. Clin Infect Dis. 2024. PMID: 38051646
Trends of pre-treatment drug resistance in antiretroviral-naïve people with HIV-1 in the era of second-generation integrase strand-transfer inhibitors in Taiwan.
Chen GJ, Cheng CY, Yang CJ, Lee NY, Tang HJ, Huang SH, Huang MH, Liou BH, Lee YC, Lin CY, Hung TC, Lin SP, Sun HY, Chang SY, Hung CC; Taiwan HIV Study Group. Chen GJ, et al. Among authors: lin cy. J Antimicrob Chemother. 2024 May 2;79(5):1157-1163. doi: 10.1093/jac/dkae086. J Antimicrob Chemother. 2024. PMID: 38546761
6,705 results